

1 Dalmore Drive,
Scoresby,
Victoria 3179
AUSTRALIA
T: +61 (0)3 9763-1287
F: +61 (0)3 9763-2817
www.generabiosystems.com

Monday 1 October 2018

**ASX Announcement – GENERA BIOSYSTEMS LIMITED (ASX: GBI)
GENERA – ANNUAL REPORT AND PROSPECTUS UPDATE**

Genera Biosystems Limited (ASX:GBI) ('Genera' or 'the Company') would like to provide the market an update on the timing of lodgement of its audited annual accounts and the proposed Non-Renounceable Entitlements Issue.

The Company is currently finalising its annual audit and currently aims to lodge its Annual Report with the ASX the week commencing 8 October 2018. The audited accounts and Annual Report are currently being finalised and a short delay will be incurred while final agreements are being put in place with existing Noteholders.

Shortly after Genera lodges its annual report with ASX it intends to lodge a prospectus with ASIC in the week of 15 October to raise up to \$11.2M via a 4 for 5 non-renounceable entitlements issue at an Issue Price of \$0.13 per new share (the "**Entitlements Issue**"). The proposed Entitlements Issue is currently expected to close by the end of October and is being conducted in order to strengthen the Company's financial position and support the planned rollout of Genera's test menu operating on the new automated Beckman Coulter system, an expansion of Genera's test development and commercialisation teams and an expansion of the AmpaSand test menu and additional partnering activities beyond the Beckman Coulter Distribution Agreement as announced to ASX on 8 May.

For further information please contact:

Mr Richard Hannebery
Chief Executive Officer
Genera Biosystems Limited
Telephone: +61 (0)3 9763 1287
www.generabiosystems.com.au

About Genera Biosystems : Genera Biosystems Limited (“GBI”) is an Australian Securities Exchange listed molecular diagnostics company, which develops, manufactures and distributes advanced PCR molecular diagnostics tests.

Genera’s single-well high multiplex AmpaSand® testing platform can detect up to 125 target analytes in a single-well of a reaction plate. Unlike traditional real-time PCR approaches, AmpaSand® single-well multiplex tests when run on a seamlessly integrated flow cytometry and liquid handling system can provide unparalleled throughput capability and cost efficiency for high volume pathology laboratories qualitative molecular testing needs.¹

Genera manufactures products in its Australian Therapeutics Goods Administration certified manufacturing facility in Scoresby, Victoria, Australia.

PapType®, an ARTG listed and CE-marked MDx test, simultaneously detects and identifies 14 high-risk types of HPV and 2 low risk HPV types in a single-well. These high-risk HPV types are responsible for 99.7% of all cases of cervical cancer.

In addition to PapType®, Genera has also commercialized and gained ARTG listing and CE mark for RTIplex™, a single-well multiplex MDx that identifies 15 common upper respiratory tract pathogens, including Influenza A & B, as well as 10 other viral and 3 bacterial disease-causing microbial targets.

Genera’s development pipeline includes a new 8-plex sexually transmitted infections panel that is expected to be available in the 2nd half of 2018, with plans to broaden the AmpaSand® test menu further to 6 highly competitive single-well multiplex MDx assays by 2019.

PapType®, RTIplex™, and the tests in development, employ the AmpaSand® biochemistry as well as Genera’s proprietary ARTG listed and CE-IVD marked QPlots™ automated analytical and reporting software that is compatible with most Laboratory Information Management Systems (‘LIMS’).

All the components of the Genera MDx system, including AmpaSand® and QPlots™, have been optimized to run on Beckman Coulter’s innovative CytoFLEX™ flow cytometry system.

¹ All ‘plate based’ Real Time PCR platforms can ‘multiplex’ up to 4 targets per well assuming 4 available channels of a Real Time PCR instrument. To multiplex greater than 4 target analytes in a test most platforms require use of additional wells of a plate to test for the additional target analytes. As such commercially, their multiplexing capability is restricted due to a direct trade-off with volume throughput per plate (96 or 384 well). Genera’s AmpaSand® technology facilitates the multiplexing of up to ~125 target analytes **in a single-well** of a plate. On a like for like basis depending on the number of target analytes detected in a multiplex assay Genera’s AmpaSand® technology facilitates > 4X relative volume throughput. High volume throughput is a key commercial consideration for all large pathology labs undertaking HPV and STI testing.